Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shares surged 6.4% after the neuroscience-focused biopharmaceutical company reported second-quarter earnings that dramatically exceeded analyst expectations. The company posted earnings per share of $1.07, beating analyst estimates of -$0.99 by $2.06.
The strong market reaction reflects investor enthusiasm over the substantial earnings beat, even as the company continues to invest heavily in its late-stage clinical programs. Xenon reported a net loss of $84.7 million for the quarter ended June 30, 2025, compared to $57.9 million for the same period in 2024, with research and development expenses increasing to $75.0 million from $49.7 million YoY.
"The completion of patient recruitment for our Phase 3 X-TOLE2 study is a significant milestone in the development of azetukalner and keeps us on track to report topline results in early 2026 in anticipation of our first potential approval and commercial product as a company," said Ian Mortimer, President and Chief Executive Officer of Xenon.
The company’s cash position remains strong with $624.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, compared to $754.4 million at the end of 2024. Management expects this will fund operations into 2027, supporting the completion of azetukalner’s Phase 3 epilepsy studies and late-stage clinical development in major depressive disorder and bipolar depression.
Xenon continues to advance its pipeline, with ongoing Phase 3 trials for azetukalner across multiple indications including focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. The company has also initiated Phase 1 studies for XEN1120 and XEN1701, targeting pain conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.